跳转至内容
Merck
CN

SML3467

Remimazolam

≥98% (HPLC)

别名:

(S)-Methyl 3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate, CNS 7054 methyl ester, CNS 7056, CNS-7054 methyl ester, CNS-7056, CNS7054 methyl ester, CNS7056, Methyl 3-{(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl}propanoate, ONO 2745, ONO-2745, ONO2745

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C21H19BrN4O2
化学文摘社编号:
308242-62-8
分子量:
439.31
UNSPSC Code:
12352200
MDL number:
MFCD18633229
NACRES:
NA.21

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

CYHWMBVXXDIZNZ-KRWDZBQOSA-N

InChI

1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1

SMILES string

CC1=CN=C2[C@H](CCC(OC)=O)N=C(C3=CC=CC=N3)C4=CC(Br)=CC=C4N12

assay

≥98% (HPLC)

form

powder

drug control

USDEA Schedule IV, kontrollierte Droge in Deutschland

Quality Level

100

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

GABAA receptor positive allosteric modulator (PAM) that causes fast onset and short duration of sedative action in vivo with rapid recovery.
Remimazolam (CNS 7056) is a benzodiazepine derivative with positive allosteric modulator (PAM) activity toward γ-aminobutyric acid type A (GABAA) receptor (pKi = 7.53/7.50/7.56 against 2.5 nM flunitrazepam for binding human/rat/yucatan micropig brain homogenates; pEC50/Emax = 6.44/375% (α1β2γ2), 6.18/186% (α2β2γ2), 6.04/210% (α3β2γ2), 5.86/289% (α5β2γ2s) by whole cell patch clamp using cells expressing respective rat αβγ complex). Intravenous injection (25 mg/kg rats, 15-30 mg/kg mice) causes fast onset and short duration of sedative action with rapid recovery when compared with midazolam.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H336

Hazard Classifications

STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000220344
0000220343
0000220344
0000220343
0000198426

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Design, Synthesis, and Biological Evaluation of Novel CNS 7056 Derivatives as Sedatives in Rats and Rabbits
Yan Liu , Xiangqing Xu , Jianyong Xie , Huan Ma , Tao Wang , Guisen Zhang , Qingeng Li
Chemical Biology & Drug Design, 88, 38-42 (2016)
Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents
Bevans T, Deering-Rice C, Stockmann C, Rower J, Sakata D, Reilly C
Anesthesia and Analgesia, 124, 1484-1490 (2017)
Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep
R N Upton , A A Somogyi, A M Martinez, J Colvill, C Grant
British Journal of Anaesthesia, 105, 798-809 (2010)
Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system
Freyer N, Knospel F, Damm G, Greuel S, Schneider C, Seehofer D, Stohr T, Petersen KU, Zeilinger K
Drug design, development and therapy, 13, 1033-1047 (2019)
CNS 7056: a novel ultra-short-acting Benzodiazepine
Anesthesiology, 107, 60-66 (2007)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持